COGT · Insider Trading
Cogent Biosciences, Inc. Common Stock
Every open-market purchase and sale reported by COGT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Karen Jean Ferrante | Director | A | +759 deriv. | — |
| 2026-08-31 | Arlene Morris | Director | MIXED | — | −$1.44M |
| 2026-07-06 | Karen Jean Ferrante | Director | A | +627 deriv. | — |
| 2026-06-11 | Arlene Morris | Director | A | +17,901 deriv. | — |
| 2026-06-11 | Christopher W. Cain | Director | A | +17,901 deriv. | — |
| 2026-06-11 | Karen Jean Ferrante | Director | A | +17,901 deriv. | — |
| 2026-06-11 | Matthew Ros | Director | A | +17,901 deriv. | — |
| 2026-06-11 | Peter Evan Harwin | Director | A | +17,901 deriv. | — |
| 2026-06-11 | Todd Shegog | Director | A | +17,901 deriv. | — |
| 2026-05-21 | Andrew R Robbins | President and CEO | G | — | — |
| 2026-04-03 | Karen Jean Ferrante | Director | A | +686 deriv. | — |
| 2026-01-22 | Fairmount Funds Management LLC | Director | Sell | −3,500,000 | −$127.40M |
| 2026-01-05 | Karen Jean Ferrante | Director | A | +643 deriv. | — |
| 2025-12-30 | Jessica Sachs | Chief Medical Officer | Sell | −82,642 | −$3.20M |
| 2025-12-30 | Evan Kearns | Chief Legal Officer | Sell | −65,000 | −$2.52M |
| 2025-12-30 | John Edward Robinson | Chief Scientific Officer | Sell | −90,000 | −$3.49M |
| 2025-12-30 | John L. Green | Chief Financial Officer | Sell | −77,000 | −$2.98M |
| 2025-12-19 | John L. Green | Chief Financial Officer | MIXED | +204,993 | −$5.72M |
| 2025-12-19 | Jessica Sachs | Chief Medical Officer | MIXED | +215,284 | −$6.10M |
| 2025-12-19 | Andrew R Robbins | President and CEO | MIXED | +657,503 | −$14.50M |
| 2025-12-19 | Evan Kearns | Chief Legal Officer | MIXED | +174,398 | −$4.95M |
| 2025-12-19 | Cole Pinnow | Chief Commercial Officer | MIXED | +169,200 | −$3.74M |
| 2025-12-19 | John Edward Robinson | Chief Scientific Officer | MIXED | +230,002 | −$5.52M |
| 2025-10-03 | Karen Jean Ferrante | Director | A | +1,642 deriv. | — |
| 2025-07-14 | Fairmount Funds Management LLC | Director | Buy | +2,777,777 | +$25.00M |
| 2025-07-02 | Karen Jean Ferrante | Director | A | +3,314 deriv. | — |
| 2025-06-05 | Christopher W. Cain | Director | A | +44,700 deriv. | — |
| 2025-06-05 | Peter Evan Harwin | Director | A | +44,700 deriv. | — |
| 2025-06-05 | Todd Shegog | Director | A | +44,700 deriv. | — |
| 2025-06-05 | Arlene Morris | Director | A | +44,700 deriv. | — |
| 2025-06-05 | Karen Jean Ferrante | Director | A | +44,700 deriv. | — |
| 2025-06-05 | Matthew Ros | Director | A | +44,700 deriv. | — |
| 2025-04-03 | Karen Jean Ferrante | Director | A | +3,788 deriv. | — |
| 2025-01-27 | John Edward Robinson | Chief Scientific Officer | A | +270,000 deriv. | — |
| 2025-01-27 | Jessica Sachs | Chief Medical Officer | A | +270,000 deriv. | — |
| 2025-01-27 | Andrew R Robbins | President and CEO | A | +915,000 deriv. | — |
| 2025-01-27 | John L. Green | Chief Financial Officer | A | +270,000 deriv. | — |
| 2025-01-27 | Cole Pinnow | Chief Commercial Officer | A | +240,000 deriv. | — |
| 2025-01-27 | Evan Kearns | Chief Legal Officer | A | +230,000 deriv. | — |
| 2025-01-15 | Cole Pinnow | Chief Commercial Officer | Buy | +43,750 | +$332.41K |
| 2025-01-03 | Karen Jean Ferrante | Director | A | +2,785 deriv. | — |
| 2024-10-02 | Karen Jean Ferrante | Director | A | +2,034 deriv. | — |
| 2024-07-02 | Karen Jean Ferrante | Director | A | +2,462 deriv. | — |
| 2024-06-13 | Matthew Ros | Director | A | +44,700 deriv. | — |
| 2024-06-13 | Karen Jean Ferrante | Director | A | +44,700 deriv. | — |
| 2024-06-13 | Peter Evan Harwin | Director | A | +44,700 deriv. | — |
| 2024-06-13 | Todd Shegog | Director | A | +44,700 deriv. | — |
| 2024-06-13 | Christopher W. Cain | Director | A | +44,700 deriv. | — |
| 2024-06-13 | Arlene Morris | Director | A | +44,700 deriv. | — |
| 2024-06-12 | Fairmount Funds Management LLC | Director | M | +1,500,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Fairmount Funds Management LLC | Director | 5,503,418 | $162.46M |
| Andrew R Robbins | President and CEO | 657,503 | $19.41M |
| John Edward Robinson | Chief Scientific Officer | 140,002 | $4.13M |
| Jessica Sachs | Chief Medical Officer | 133,938 | $3.95M |
| John L. Green | Chief Financial Officer | 131,834 | $3.89M |
| Evan Kearns | Chief Legal Officer | 109,398 | $3.23M |
| Cole Pinnow | Chief Commercial Officer | 97,450 | $2.88M |
| Arlene Morris | Director | 45,510 | $1.34M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the COGT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.